Recce Pharmaceuticals Valuation
Is RCE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RCE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate RCE's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate RCE's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RCE?
Other financial metrics that can be useful for relative valuation.
| What is RCE's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | AU$130.53m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 19.1x |
| Enterprise Value/EBITDA | -12.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does RCE's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 25.5x | ||
VIT Vitura Health | 0.6x | n/a | AU$72.0m |
ALA Arovella Therapeutics | 69.3x | n/a | AU$136.5m |
PER Percheron Therapeutics | 30.4x | 14.8% | AU$69.4m |
VLS Vita Life Sciences | 1.7x | n/a | AU$126.0m |
RCE Recce Pharmaceuticals | 19.3x | -20.8% | AU$130.5m |
Price-To-Sales vs Peers: RCE is good value based on its Price-To-Sales Ratio (19.3x) compared to the peer average (25.5x).
Price to Earnings Ratio vs Industry
How does RCE's PE Ratio compare vs other companies in the AU Pharmaceuticals Industry?
Price-To-Sales vs Industry: RCE is expensive based on its Price-To-Sales Ratio (19.3x) compared to the Australian Pharmaceuticals industry average (5.8x).
Price to Sales Ratio vs Fair Ratio
What is RCE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 19.3x |
| Fair PS Ratio | 0.6x |
Price-To-Sales vs Fair Ratio: RCE is expensive based on its Price-To-Sales Ratio (19.3x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.